SITC's 40th Annual Meeting Showcases Over 1,300 Clinical Abstracts

Society for Immunotherapy of Cancer's 40th Anniversary Meeting

The Society for Immunotherapy of Cancer (SITC) has announced an impressive milestone for its upcoming 40th Anniversary Annual Meeting taking place from November 5 to 9, 2025, in National Harbor, Maryland, along with virtual participation options. The SITC has received an unprecedented number of more than 1,300 abstract submissions for this event, a testament to the growing interest and advancements in cancer immunotherapy.

SITC's Vice President, Dr. Sandra Demaria, expressed excitement about this year’s clinical Late-breaking Abstracts (LBA), highlighting their significance in showcasing pioneering research. The abstracts selected for presentation will focus exclusively on recent data from interventional clinical trials involving human participants. This initiative aligns with SITC’s mission to accelerate the approval of 100 innovative therapies by 2034 and enhance scientific dialogue in the field of immunotherapy.

Among the notable presentations is the examination of invikafusp alfa, a novel TCR β-chain-targeted bifunctional antibody, in patients showing high tumor mutational burden (TMB-H) during a Phase 1/2 trial. Another key presentation will unveil a first-in-human dose escalation study of mRNA-LNP MT-302, investigating its effects on solid tumors.

Significant findings from the HARMONi-A study will also be presented, comparing the combination of ivonescimab and chemotherapy versus chemotherapy alone for patients with EGFR-positive NSCLC. Furthermore, the conference will spotlight coformulation strategies combining favezelimab and pembrolizumab as neoadjuvant therapies for resectable cutaneous squamous cell carcinoma (cSCC).

The full array of regular and Young Investigator Award abstracts will be available prior to the event, specifically on November 4, with the LBA clinical abstracts released on November 7. Sessions will include oral presentations on critical findings, running from November 7 to 8 at the Gaylord National Resort and Convention Center. Late-breaking abstracts will also be featured through posters in the Exhibit and Poster Hall, demonstrating the breadth of research advancements.

To facilitate participation, SITC encourages registration for anyone interested in the latest developments in immunotherapy. This event not only represents a remarkable gathering of professionals dedicated to fighting cancer but also serves as a platform to celebrate the progress made over the past 40 years in improving patient outcomes.

About SITC:
The Society for Immunotherapy of Cancer, established in 1984, stands as a cornerstone organization focused on advancing the science behind cancer immunotherapy. As a not-for-profit 501(c)(3) entity, SITC aims to unite scientists, clinicians, and patient advocates to foster collaboration and accelerate breakthroughs in cancer treatment. With the ongoing commitment to ushering in a new era of cancer care, SITC continues to lead initiatives that promote the rapid development and application of immunotherapeutic strategies, ensuring that cutting-edge therapies are accessible to patients worldwide.

For more detailed information about the upcoming meeting, or to register for attendance, visit SITC's official website. Engage with SITC on various social media platforms for the latest updates.